Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

motilin receptor found on smooth muscle cells of the GI tract and elements of the enteric nervous system. The clinical observation that the macrolide antibiotic erythromycin, a motilin receptor agonist, accelerates gastric emptying in patients with diabetic gastroparesis (impaired gastric emptying) has resulted in efforts to develop non-antibiotic macrolides (motilides) as prokinetic agents. PF-04548043 is a potent, selective motilin receptor agonist that is chemically stable and orally bioavailable and lacks antibiotic activity. In preclinical studies, PF-04548043 showed an improved safety profile relative to erythromycin and accelerated gastric emptying, suggesting that it may provide symptom relief in several GI diseases.

About GERD

Although the pathophysiology underlying GERD is not fully understood, it is clear that GERD is not due to acid hyper-secretion, but rather, is due to a combination of disordered upper GI tract motility, resulting in increased ingress of gastric contents into the lower esophagus, together with impairments in esophageal clearance and protection mechanisms. Increased exposure to gastric contents, coupled with reduced ability to clear the bolus, appears to precipitate reflux symptoms. Despite adequate control of intra-gastric acidity with proton pump inhibitors, a proportion of GERD patients continues to have residual symptoms. Through improvement of GI motility and increases in the rate of gastric emptying, PF-04548043 has the potential to reduce the exposure of the esophagus to acidic and weakly acidic reflux and this may improve the symptoms of GERD.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 in
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015 According to a new ... Technology (RF, Microwave, Cryoablation, Others), Department (Interventional Radiology, Surgery, ... Metastasis) - Global Forecasts to 2019", published by MarketsandMarkets, ... $462.0 Million growing at a CAGR of 11.50% by ... 57 figures spread through 195 pages and in-depth TOC ...
(Date:3/26/2015)... , March 26, 2015  CCS Medical ("CCS"), ... medical supplies for patients with chronic conditions, has ... Chief Executive Officer, effective March 23.  Mr. Carson ... company, where he was President of Operations. ... President and Executive Vice President of Operations at ...
(Date:3/26/2015)... 26, 2015  Desert Valley Medical Center, named a ... is the first U.S. hospital to deploy the ... to help clinicians prevent hospital acquired pressure ulcers. ... , is a community hospital serving some higher ... Leaf Patient Monitor in the hospital,s emergency department enables ...
Breaking Medicine Technology:Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4CCS Medical Team Hires Industry Operator Rodney Carson as CEO 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 3
... landmark trial provide important insight for physicians in treating ... Corporation (NYSE: BSX ) today welcomed the ... this week,s issue of the New England Journal of ... Cardiovascular Research Foundation with research grant support from Boston ...
... over linezolid in resistance acquisition by Staph aureus ... meetingSAN DIEGO, Calif., May 6 Trius Therapeutics, ... the treatment of serious bacterial infections, announced today ... lead program, torezolid (TR-701), will be presented in ...
Cached Medicine Technology:Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 2Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 3Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 4Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 5Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases 2Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases 3
(Date:3/26/2015)... In the key developed markets, the hypertension ... is set to decrease through 2020 at a negative CAGR ... expected up to 2017 at a 2.6% CAGR and a ... to the surging penetration of fixed-dose combination drugs like Azor, ... Benicar HCT, and Tekamlo), a hike in the prevalence population ...
(Date:3/26/2015)... March 26, 2015 In preparation for ... Fitness Revolution, founded by Samir Becic, has issued ... own personal health and fitness, as well as their ... The list includes Sen. Ted Cruz, who has officially ... as all other politicians who have shown interest in ...
(Date:3/26/2015)... March 26, 2015 With the rapidly ... role in managing their care, its not just doctors ... with no medical background want a piece of the ... has seen an increase in franchises purchased by people ... , Why Chiropractic? , Chiropractic is an exploding ...
(Date:3/26/2015)... The beauty industry united on Saturday, ... who revolutionized the business of beauty education. The Beauty ... of Pivot Point International, Inc. Passage’s wife Lenie, and ... Held at the Art Institute of Chicago, the sold-out ... and media leaders and served as the signature gala ...
(Date:3/26/2015)... March 26, 2015 LinkToBanking, a ... industries, names Tom Fleming as Chairman of the ... Board, effective immediately. With their combined knowledge ... services industry, Mr. Fleming and Mr. Casares will ... services to cannabis related businesses. , About Tom ...
Breaking Medicine News(10 mins):Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:HealthSource Chiropractic Franchise Expands National Footprint as Investors Buy In 2Health News:HealthSource Chiropractic Franchise Expands National Footprint as Investors Buy In 3Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 3Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 3
... as likely as whites or Hispanics to develop condition ... are almost twice as likely to develop severe sepsis ... severe sepsis than either whites or Hispanics, new research ... the bloodstream accompanied by acute organ dysfunction. The study, ...
... Warwick and the Indian Institute of Technology Kanpur have discovered ... safely through our blood stream can, in certain circumstances, collapse ... lines of iron rust. This process could provide the first ... cause some forms of Parkinsons & Alzheimers and Huntingtons diseases. ...
... Congresswoman,Stephanie Tubbs Jones announced that six new construction ... Stokes Cleveland VA Medical,Center by the Department of ... made possible by a $397 million increase over ... final 2008,Appropriations bill signed into law in December., ...
... announced third quarter and nine months results for fiscal,2008. ... sales,increased 30.9% to $48.5 million versus $37.0 million for ... quarter was $1.5 million, equal to $0.15 per,diluted share, ... share,for the third quarter of fiscal 2007., For ...
... Mesa Laboratories,Inc. (Nasdaq: MLAB ) today announced ... quarterly cash dividend of ten cents per share ... shareholders of record at the close of,business on ... manufactures and markets,electronic instruments for industrial, pharmaceutical and ...
... can occur in patients (both children and adults) ... they have been pre-medicated with corticosteroids and antihistamines, ... at the University of Michigan Health Systems in ... at our institution who have a history of ...
Cached Medicine News:Health News:Blacks More Likely to Die of Severe Sepsis 2Health News:Iron banded worms drying out of blood could be linked to Parkinson's and Alzheimer's 2Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 2Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 3Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 4Health News:Allergic-like reactions occur in premedicated patients 2
CritiCool™ offers precise cooling to the programmed target temperature by applying temperature control algorithm....
Inquire...
Whole blood tube use for microbiology...
BD Vacutainer® Specialty Tubes - Other - Glass...
Medicine Products: